Abstract
Spiraling drug developmental costs and lengthy time-to-market introduction are two critical challenges facing the pharmaceutical industry. The clinical trials success rate for oncology drugs is reported to be 5% as compared to other therapeutic categories (11%) with most failures often encountered late in the clinical development process. PET and SPECT nuclear imaging technologies could play an important role in facilitating the drug development process improving the speed, efficiency and cost of drug development. This review will focus on recent studies of PET and SPECT radioligands in oncology and their application in the investigation of tumor biology. The use of clinically-validated radioligands as imaging-based biomarkers in oncology could significantly impact new cancer therapeutic development.
Keywords: PET, SPECT, radioligands, tumor imaging, tumor biomarkers, drug development
Current Computer-Aided Drug Design
Title: PET and SPECT Imaging of Tumor Biology: New Approaches Towards Oncology Drug Discovery and Development
Volume: 4 Issue: 1
Author(s): Marcian E. Van Dort, Alnawaz Rehemtulla and Brian D. Ross
Affiliation:
Keywords: PET, SPECT, radioligands, tumor imaging, tumor biomarkers, drug development
Abstract: Spiraling drug developmental costs and lengthy time-to-market introduction are two critical challenges facing the pharmaceutical industry. The clinical trials success rate for oncology drugs is reported to be 5% as compared to other therapeutic categories (11%) with most failures often encountered late in the clinical development process. PET and SPECT nuclear imaging technologies could play an important role in facilitating the drug development process improving the speed, efficiency and cost of drug development. This review will focus on recent studies of PET and SPECT radioligands in oncology and their application in the investigation of tumor biology. The use of clinically-validated radioligands as imaging-based biomarkers in oncology could significantly impact new cancer therapeutic development.
Export Options
About this article
Cite this article as:
Van Dort E. Marcian, Rehemtulla Alnawaz and Ross D. Brian, PET and SPECT Imaging of Tumor Biology: New Approaches Towards Oncology Drug Discovery and Development, Current Computer-Aided Drug Design 2008; 4 (1) . https://dx.doi.org/10.2174/157340908783769265
DOI https://dx.doi.org/10.2174/157340908783769265 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Radiosensitization of Prostate Cancer by Soy Isoflavones
Current Cancer Drug Targets Protein Transduction Domains: Applications for Molecular Medicine
Current Gene Therapy P53 Family: At the Crossroads in Cancer Therapy
Current Medicinal Chemistry OX40 and OX40L Interaction in Cancer
Current Medicinal Chemistry Targeting Dopaminergic System for Treating Nicotine Dependence
Central Nervous System Agents in Medicinal Chemistry Insect Peptides – Perspectives in Human Diseases Treatment
Current Medicinal Chemistry Chelating Agents and their Use in Radiopharmaceutical Sciences
Mini-Reviews in Medicinal Chemistry The Pharmacogenomics “Side-effect” of TP53/EGFR in Non-small Cell Lung Cancer Accompanied with Atorvastatin Therapy: A Functional Network Analysis
Anti-Cancer Agents in Medicinal Chemistry Intravesical Chemotherapy and Chemohyperthermia in Non-Muscle-Invasive Bladder Cancer; An Overview on Drug Administration Technologies and Pharmacokinetics
Current Drug Metabolism Voltage-Gated Ion Channels, New Targets in Anti-Cancer Research
Recent Patents on Anti-Cancer Drug Discovery Recent Findings on the Application of Toll-like Receptors Agonists in Cancer Therapy
Current Medicinal Chemistry Specific Targeting of HER2-Positive Head and Neck Squamous Cell Carcinoma Line HN5 by Idarubicin-ZHER2 Affibody Conjugate
Current Cancer Drug Targets Non-steroidal Anti-Inflammatory Drugs and Melanoma
Current Pharmaceutical Design Integrins in Drug Targeting-RGD Templates in Toxins
Current Pharmaceutical Design Heat Shock Protein 70s as Potential Molecular Targets for Colon Cancer Therapeutics
Current Medicinal Chemistry Epithelial Mesenchymal Transition in Cancer Progression: Prev entive Phytochemicals
Recent Patents on Anti-Cancer Drug Discovery Platelet-Rich and Platelet-Poor Plasma Might Play Supportive Roles in Cancer Cell Culture: A Replacement for Fetal Bovine Serum?
Anti-Cancer Agents in Medicinal Chemistry subject Index To Volume 3
Current Drug Targets Non-invasive Biodiversified Sensors: A Modernized Screening Technology for Cancer
Current Pharmaceutical Design Prognostic Value and Clinicopathological Differences of Bmi1 in Gastric Cancer: A Meta-analysis
Anti-Cancer Agents in Medicinal Chemistry